On September 20, 2024, bluebird bio, Inc. entered into a Master Services Agreement with Henogen SRL, a subsidiary of Thermo Fisher Scientific, to manufacture lentiviral vector (LVV) used in bluebird bio's gene therapy product LYFGENIA. The agreement, effective as of September 15, 2024, supersedes the previous manufacturing contract with Henogen that expired on the same date. Henogen will be responsible for the production of LVV, including quality control, assurance, validation activities, stability testing, packaging, shipping, and other related services for both clinical and commercial use. The agreement allows for the creation of individual project agreements for specific products and requires bluebird bio to provide a 12-quarter rolling forecast for commercial LVV orders, with certain binding and semi-binding forecast periods. The contract is set to last until September 15, 2029, with automatic renewal for additional two-year terms unless terminated by either party due to material breach, bankruptcy proceedings, or force majeure events. It also includes standard provisions such as representations, warranties, limitations of liabilities, confidentiality, indemnity obligations, and other customary terms.

On September 20, 2024, bluebird bio, Inc. entered into a Master Services Agreement with Henogen SRL, a subsidiary of Thermo Fisher Scientific, to manufacture lentiviral vector (LVV) used in bluebird bio's gene therapy product LYFGENIA. The agreement, effective as of September 15, 2024, supersedes the previous manufacturing contract with Henogen that expired on the same date. Henogen will be responsible for the production of LVV, including quality control, assurance, validation activities, stability testing, packaging, shipping, and other related services for both clinical and commercial use. The agreement allows for the creation of individual project agreements for specific products and requires bluebird bio to provide a 12-quarter rolling forecast for commercial LVV orders, with certain binding and semi-binding forecast periods. The contract is set to last until September 15, 2029, with automatic renewal for additional two-year terms unless terminated by either party due to material breach, bankruptcy proceedings, or force majeure events. It also includes standard provisions such as representations, warranties, limitations of liabilities, confidentiality, indemnity obligations, and other customary terms.